Background: Multicenter randomized controlled trials (RCTs) for asthma management that incorporate usual-care regimens could benefit from standardized application of evidence-based guidelines. Objective: We sought to evaluate performance of a computerized decision support tool, the Asthma Control Evaluation and Treatment (ACET) Program, to standardize usual-care regimens for asthma management in RCTs. Methods: Children and adolescents with persistent uncontrolled asthma living in urban census tracts were recruited into 3 multicenter RCTs (each with a usual-care arm) between 2004 and 2014. A computerized decision support tool scored asthma control and assigned an appropriate treatment step based on published guidelines. Control-level determinants (symptoms, rescue medication use, pulmonary function measure, and adherence estimates) were collected at visits and entered into the ACET Program. Changes in control levels and treatment steps were examined during the trials. Results: At screening, more than half of the participants were rated as having symptoms that were not controlled or poorly controlled. The proportion of participants who gained good control between screening and randomization increased significantly in all 3 trials. Between 51% and 70% had symptoms that were well controlled by randomization. The proportion of well-controlled participants remained constant or improved slightly from randomization until the last posttreatment visit. Nighttime symptoms were the most common control-level determinant; there were few (<1%) instances of complete overlap of factors. FEV 1 was the driver of control-level assignment in 30% of determinations. Conclusion: The ACET Program decision support tool facilitated standardized asthma assessment and treatment in Key Words: Asthma guidelines, asthma control, decision support, inner-city asthma Asthma is a common, complex, and costly chronic condition in the United States, resulting in nearly 2 million acute-care visits and $56 billion in overall costs each year. [1] [2] [3] Uncontrolled asthma disproportionately affects children from minority groups (predominately African American), low-income families, and single-parent households with financial hardship and familial strain. [4] [5] [6] Successful asthma management is often complex, typically requiring repeated administration of multiple medications and use of complicated devices. National and international evidence-based guidelines have been developed to assist health care providers and patients to gain control of asthma symptoms; however, they are often not implemented. [7] [8] [9] [10] [11] [12] Implementation of evidence-based clinical practice guidelines for managing chronic diseases is challenging in both primary and specialist care settings. 13, 14 Although guidelines for the diagnosis and management of asthma, (National Heart, Lung, and Blood Institute and produced by the National Asthma Education and
were published in 1991 and updated in 2007, dissemination strategies, educational promotions, seminars, and numerous supplemental materials have not resulted in effective guideline implementation. 9, 10, 13 It is also unclear how consistent application of guidelines using standardized data collection and decision making would improve long-term asthma control.
The National Institute of Allergy and Infectious Diseasesfunded Inner-City Asthma Consortium (ICAC), which was initiated in 2002, seeks to (1) identify and evaluate immunebased therapy for treatment of asthma in inner-city children, (2) identify and determine forms of immune-based therapies most likely to promote disease prevention and control, and (3) determine both overall and potentially unique mechanisms of immune-based therapies associated with asthma pathogenesis in inner-city children. 15 We designed randomized controlled trials (RCTs) that used an innovative paradigm; asthma control was assessed and treatment adjusted at regular intervals throughout the trial duration in both the intervention and usual-care control arms. A computerized decision support tool to operationalize the NAEPP asthma guidelines to both gain and maintain asthma control throughout ICAC trials was designed. The treatment algorithm included elements from the EPR-2 and EPR-3 guidelines: daytime and nighttime symptom frequency, short-acting bagonist (SABA) rescue use, FEV 1 , and systemic corticosteroid treatment of acute exacerbations.
It was our objective to have the computerized decision support tool permit effective and standardized longitudinal treatment step determination required to gain and maintain asthma control among high-risk inner-city children and adolescents. This report focuses on implementation and performance of the decision support tool to collect components of asthma control and then to adjust appropriate treatment among participants enrolled in 3 published ICAC multicenter trials using independent patient cohorts. Each trial implemented a usual-care regimen standardized across the ICAC centers to address the following trial aims: (1) value of a biomarker to guide treatment compared with usual care alone, (2) benefit of an immune-based therapy when added to usual care over 12 months, and (3) benefit of immune-based versus step-up therapy for prevention of severe fall exacerbations when added to usual care.
METHODS
Participants with persistent uncontrolled asthma, aged 6 to 20 years and living in urban census tracts with at least 20% poverty rate, were recruited at 10 geographically dispersed ICAC clinical centers between September 2004 and May 2014; each center had 2 to 4 investigators certified to conduct protocol visits. Participants all had a physician's diagnosis or a history of asthma symptoms for more than 1 year. All trials used a computerized decision support tool constructed to assign an asthma control level and an appropriate treatment step. The trials were the Asthma Control Evaluation (ACE), the Inner-City Anti-IgE Therapy for Asthma (ICATA), and the Preventative Omalizumab or Step-up Therapy for Severe Fall Exacerbations (PROSE) trials (Table I) . Protocol designs and outcomes are published elsewhere. [16] [17] [18] Consistent with NAEPP guidelines, 7 asthma control determinants were collected at each visit and entered into the Asthma Control Evaluation and Treatment (ACET) Program. The ACET Program, including asthma control levels, linkage to treatment steps, and criteria for prescribing oral corticosteroids for asthma exacerbations, was developed by a small group of ICAC clinical investigators who were not involved in care delivery at the trial sites. Training scenarios and case studies using the ACET Program were then provided to the ICAC site investigators and staff through manuals of operation and protocol orientations.
The ACET Program calculated overall asthma control levels based on the collected determinants and generated treatment step options according to standardized algorithms defined a priori in the protocols; algorithms were similar for the baseline, randomization, and follow-up visits. Asthma control level was based on 3 determinants: days with symptoms or albuterol rescue use, nights of sleep disruption or albuterol use for awakening, and FEV 1 . The ACET Program used in the PROSE trial also included oral corticosteroid treatment for acute exacerbations in the 6 months before the screening visit and in the intervals between subsequent visits. Symptoms were based on 2-week recall at the visit and scored on a scale of 1 to 4, with a score of 1 representing good control. The highest determinant defined the overall asthma control level (Table II) . The ACET Program was used to adjust treatment level, starting with the screening visit in all trials.
Study physicians were given the opportunity to override the treatment algorithm at each visit. Reasons for changes in ACET Program recommendations included physician-corrected symptoms and adherence data [16] [17] [18] (Table III) or clinical judgment resulting from findings on physical examination.
Control levels were then matched with medication treatment steps (Tables  II and IV) derived from the EPR-2 guidelines and ranged from step 0 (asneeded albuterol only) to step 6 (high-dose inhaled corticosteroids [ICSs] plus long-acting b-agonist plus a second controller medication). There were slight differences in the treatment steps among the trials, most notably in the PROSE trial, which did not use low-dose ICS plus long-acting b-agonist as a treatment step (Tables I and IV) . 18 Although all investigational medications were provided for ICAC trial participants, regularly prescribed guidelines-based medications for usual care were obtained by participants in the ICATA and PROSE trials from retail pharmacies through insurance coverage; all usual-care guidelines-based asthma medications were provided to ACE trial participants.
All 3 trials had an intervention group and control (guidelines-based usual care) group. Data from each trial include all participants (intervention and guidelines-based usual care) and all visits for the evaluation of and change in asthma control from screening to randomization. For the ACE and ICATA trials, data are also presented on the change in control from the first postrandomization visit to the last visit for participants in the guidelinesbased usual-care group only. These control-level data were used to adjust treatment step after randomization throughout the trials. No postrandomization data are presented for the PROSE trial because of the study cohort design.
Adherence was estimated either by monitoring medication use from builtin dose counters on controller medications and/or administration of a structured questionnaire by trained ICAC coordinators. Adherence was greater than 80% in all 3 trials and did not vary significantly throughout the trials. [16] [17] [18] Mean ACE adherence was 86.6% (SD, 27.7%) 16 ; ICATA trial controller adherence was 84.6% in the omalizumab arm and 88.6% in the placebo injection arm. 17 Median PROSE guidelines-directed usual care adherence was 92.1% (interquartile range, 82.2% to 97.9%), and median inhaler counter information for ICS boost use was 82.4% (interquartile range, 51.6% to 115.4%). 18 
Definition of asthma control level
Well-controlled asthma was defined based on determinants in the impairment domain only for the ACE and ICATA trials and also based on systemic corticosteroid use for the PROSE trial (risk domain, Table II ). Asthma symptoms were determined to be well controlled (ie, control level 1, Table II ) when a participant had minimal daytime symptoms (0-3 days in the previous 2 weeks), 0 to 1 nighttime symptoms in the previous 14 nights, and an FEV 1 of 80% to 85% of predicted value or greater.
Statistical analyses
Descriptive statistics are presented as frequencies and percentages for categorical variables and means (SDs) or medians (first-third quartiles) according to the distribution of the continuous variable. Normality was determined by visually assessing the skewness of variables. Demographics, baseline characteristics, and clinical factors influencing the ACET Program were compared between studies by using the Kruskal-Wallis test for continuous and the x 2 test for categorical variables. To visualize the relationships (intersections, unions, and disjoints) between each ACET impairment domain, we generated area-proportional Venn diagrams with circles. All statistical analyses were conducted within the R software environment (version 3.4.1), and figures were constructed by using lattice 19 and the eulerr add-on library. 20 
RESULTS
Data were available on 1443 participants distributed among the 3 trials. [16] [17] [18] Participants were predominantly black or Hispanic Increase controller regimen by 3 steps* Increase controller regimen by 2 steps* *Treatment step includes prednisone at the physician's discretion in combination with a treatment increase.
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and highly sensitized to common aeroallergens. There were a few small but statistically significant differences among the groups, some of which (age and asthma duration) were related to differences in study design and key inclusion criteria. More than half of the participants resided in households with annual incomes of less than $15,000. In addition, asthma morbidity was high, with mean Asthma Control Test scores of less than 20 and approximately 4 days of symptoms per 2 weeks reported across all trials. ACE trial participants were slightly more symptomatic compared with those in the ICATA and PROSE trials. Pulmonary function showed mild obstruction evidenced by slightly reduced FEV 1 /forced vital capacity ratios in all trials, although FEV 1 was in the normal range and there were no differences in spirometric measures among the trials (see Table E1 in this article's Online Repository at www.jacionline.org). At the screening visit, less than 30% of participants were rated as control level 1 (well controlled, see Table E2 in this article's Online Repository at www.jacionline.org). By using the treatment algorithms, the proportion of participants who then gained asthma control (control level 1) between the screening and randomization visits increased significantly in all trials; participants who gained control came from all 3 higher control levels in similar Proportion and number of study participants who were determined to be at control levels (CLs) 1 to 4 at the screening visit, randomization, and first and last postrandomization visits. In general, participants that finished at CL1 came from all 4 control levels (CL1 to CL4) at screening. CL1 is defined as well controlled, and CL4 is defined as poorly controlled. An interactive version of the figure can be found at https://rhoinc.github.io/asthma-control-graphic/.
proportions (Fig 1) . Between 51% (ICATA and PROSE trials) and 70% (ACE trial) were classified as control level 1 at the randomization visit (Fig 1 and see Table E2 , A, in this article's Online Repository at www.jacionline.org). Moreover, the proportion of participants with well-controlled symptoms remained constant or improved slightly from randomization until the last posttreatment visit for the ACE and ICATA trials. Fewer patients' symptoms remained poorly controlled over the duration of the treatment period, with the largest decrease occurring between the screening and randomization visits (see interactive Fig 1 at https://rhoinc.github.io/asthma-control-graphic/, and see Table  E2 ). In all trials the mean treatment step recommended by the ACET Program increased from screening to randomization visits, and the corresponding control level improved (see Table E2 ). For the ACE and ICATA trials, application of the ACET Program was associated with stable or slight further improvement in control level with a corresponding decrease in treatment step by trial's end. In the PROSE trial the protocol prohibited a decrease in treatment step during the 16-week treatment intervention phase, and therefore data are not shown for the end-of-trial results; in addition, the PROSE trial's primary outcome was prevention of fall asthma exacerbations and not symptom control (Table I) . Although ACET Program treatment adjustments made at the screening visit were sufficient to gain control for most participants, more than one third required a further increase in treatment step at the randomization visit. The initial treatment step remained unaltered at randomization for a variable proportion of participants, ranging from 52% (ACE trial) to 22% (ICATA trial). Fewer than 20% of participants required 2 or more treatment step increases at randomization.
The mean duration of the run-in period varied among the trials because of design differences. For the ACE and ICATA trials, the mean run-in period was 20 and 30 days, respectively. The PROSE trial had a substantially longer run-in period (mean, 145 days) to allow for cohort assembly and multiple visits to adjust treatment and stabilize care before the ''start of school'' study drug administration.
The contribution of the various determinants (daytime symptoms, nighttime symptoms, and pulmonary function) of overall asthma control level was examined. Because all factors needed to be concordant to achieve level 1, we examined the determinants driving control attribution at levels 2, 3, and 4. As shown in Fig 2, an individual determinant was more likely the driver of control levels. Nighttime symptoms were the most common determinant, and there were few (<1%) instances of complete overlap. Moreover, FEV 1 was the driver of the control level in approximately 30% of determinations. The contributions of FEV 1 and nighttime symptoms were more evident among those groups with poorer control (see Figs E1 and E2 in this article's Online Repository at www.jacionline.org). Variability among the trials with respect to the primary determinant of control level was due to differences in protocol design. More specifically, the apparent small proportion of instances in the ACE trial in which spirometry alone determined control (see Fig E1) was due to 2 treatment steps (steps 1 and 2) using the same FEV 1 cut point (80%). Irrespective of protocol design differences, data show that the ACET Program performed consistently to help gain asthma control with standardized medication adjustments across sites in all 3 ICAC trials and reduction of participants remaining at control level 4 (P value for each trial was <.001 for control gain between screening and randomization; Fig 1 and see Table E2 , A).
Among more than 3000 visits in each trial with ample opportunity for ACET Program application, study physician overrides occurred in relatively few instances (Table V) . The study physician infrequently revised the symptom report (8.1%); but when change occurred, about one third of the time, it resulted in control level alteration (Table V) . Likewise, study physicians agreed with the ACET Program step recommendations in 90% or more of the visits. Poor medication adherence affected treatment algorithm choices in 5% to 10% of visits (Table V) . In the PROSE trial reported treatment with systemic corticosteroids was used as a factor in the treatment algorithm in 15% of applications.
DISCUSSION
We provide evidence that when current asthma treatment guidelines are operationalized for usual-care arms using a computerized decision support tool during multicenter RCT visits, good asthma control is gained and maintained in most inner-city children, adolescents, and young adults. Parent-and patient-provided answers to questions about daytime and nighttime symptoms, along with FEV 1 , yielded necessary information to determine asthma control level. Despite studying a high-risk population, between 50% and 70% of participants gained asthma control within 3 to 5 weeks after enrollment with careful adherence to ACET Program step recommendations. Moreover, asthma control was maintained throughout the trial duration by more than 50% of the participants. A higher proportion of ACE trial J ALLERGY CLIN IMMUNOL VOLUME 143, NUMBER 5 participants gained control between screening and randomization compared with ICATA and PROSE trial participants. This finding might in part be due to supplying all guidelines-based controllers to ACE trial participants and only prescribing these medications in the others. Nonetheless, the ACET Program performed well in all trials, despite differences in study entry criteria and design, suggesting its effectiveness to standardize usual-asthma care regimens in large RCTs and applicability for comparable study designs.
The allergists and pulmonologists who reviewed the ACET Program results agreed with algorithm performance to a high degree. Disagreements about symptom reports resulted in a change in control-level determination in less than 10% of ACET Program applications; the occurrence of step decision override was between 5% and 10% in more than 10,000 control and treatment assessments. Strict adherence to protocols in clinical trials is essential to obtaining accurate and meaningful data in treatment comparisons, especially when new approaches are added to standard of care. The ACET Program's electronic decision support algorithm provided a mechanism to accurately monitor treatment decisions, minimize variability in decision making across multiple centers, study the alignment of decision support with clinical judgment, and determine when adjustments were made because of poor participant adherence versus symptom or exacerbation occurrences.
ICAC developed the ACET Program to operationalize the NAEPP guidelines before publication of official step recommendations. We designed an easy-to-apply framework that used patient responses to standardized questions and FEV 1 to determine the asthma control level and medication step. Our workflow included entry of patient/parent-reported responses into the program by research assistants and brief validation by the investigator. An asthma treatment plan with specific controller medications and doses was immediately provided; physician verification and either acceptance or revision of treatment step was possible. ACET Program performance was stable over the course of 3 clinical trials, with discrete patient cohorts ranging from ages 6 to 20 years, suggesting a robust and easy-to-use algorithm. Importantly, once the ACET Program provided an initial treatment step, a substantial percentage of trial participants, largely high-risk inner-city asthmatic patients, gained symptom control. Further treatment adjustments using the ACET Program throughout the trial continued to maintain asthma control for 6 to 12 months in the majority of participants.
The ACET Program relied on daytime and nighttime asthma symptom self-reports and/or SABA rescue use over the 2 weeks before the visit, as well as addition of FEV 1 and systemic corticosteroid courses. An important feature of the ACET Program is that control levels were based on the greatest number of days and nights with symptoms, the lowest FEV 1 measure, and estimated medication adherence rather than a composite score (eg, the Asthma Control Test and Asthma Control Questionnaire). Of note, the contribution of each asthma control determinant was not equivalent and varied somewhat according to study design differences. For instance, spirometry alone influenced the control level and subsequent treatment step in a minority of instances in the ACE trial, in which only 2 treatment steps could be defined by means of spirometry. In addition, ACE trial participants had to demonstrate good control (level 1) for 2 consecutive visits to step down treatment, which greatly reduced the number of participants who decreased treatment step. The PROSE trial had a much longer run-in period (mean, 145 days vs 20 or 30 days in the ACE and ICATA trials), and this accommodated either 2 or 3 treatment step adjustments before randomization. Nevertheless, the ACET Program performed in a consistent robust fashion, even though minor differences in study design influenced treatment patterns among the 3 ICAC trials.
There are some limitations to our study. First, all ICAC trial participants were managed by using the ACET Program, and therefore there was no non-ACET Program control group. As observed in other RCTs, asthma control can improve as a result of trial participation alone (regression to the mean) without the application of computerized decision support. 21 An RCT designed to compare the ACET Program with standard care without decision support would be necessary to validate the effectiveness of the ACET Program. However, advantages of the ACET Program include standardized data collection of symptoms, lung function measures, and exacerbations and alignment of treatment with these parameters. Population-, patient-, and clinician-level data can be obtained, allowing for longitudinal measure of protocol adherence and treatment response.
Next, all analyses were conducted in the context of RCTs, with care provided by asthma specialists at regularly scheduled visits. It is unclear whether the same degree of ACET Program use would occur in primary care or nonresearch settings. 22, 23 The high fidelity of ACET Program performance might have been due in part to clinical trial infrastructure. Patients who elect to join clinical trials can have different psychosocial and environmental characteristics than the nonparticipant population. Although we do not have data on nonparticipants, the 3 ICAC RCTs had a variety of entry criteria, and these differences should help minimize some of the bias and enhance generalizability. Although EPR-3 guidelines have been widely disseminated, implementation by health care providers and treatment plan use by patients has lagged behind. Previous studies indicate that even when patients meet the criteria for daily controller medications, up to half report not being prescribed or using a controller. 11, 24 In addition, many patients report frequent SABA use, suggesting less than optimal asthma control. 25, 26 Equipping health care providers with tools that facilitate determination of asthma control and then linking control level to an evidencebased treatment step care plan could improve compliance with guidelines and appropriate use of controller medications. 13, 14 From an asthma population management perspective, ACET Program use would allow more specific data quantitation and identification of patients whose symptoms were not well controlled and facilitate evaluation of those parameters and potential reasons contributing to those causes, such as frequent exacerbations that are refractory to conventional therapy, persistent symptoms caused by inadequate controller adherence, and overall poor control with many features that would lead to assessment of the environment and social determinants of health.
Our ACET Program could be adapted to clinical practice with a few modifications. In ambulatory settings patientreported data can be completed in the waiting room or at visit check-in by clinic/office personnel and verified by a prescriber. Nevertheless, system integration of the treatment algorithm into the electronic health record (EHR) would be necessary to optimize its use. Other investigators have developed such tools but have largely focused on implementation rather than actual effect on clinical outcomes. 27, 28 Decision support tools are often unwieldy for prescribers to use because of the need to shift from paper-based to electronic-based data collection, complex interfaces, and lack of direct linkage from control assessment to suggested treatment. 9, 14, 29, 30 An asthma decision support tool similar to the ACET Program was integrated into the EHR (EPIC) at a large children's hospital through a link to an external Internet-based program. 22 Symptom data and SABA use are directly added to the program by the patient/ parent, with spirometry data directly imported from the EHR. The decision support is run by the health care provider or ancillary personnel. In addition, ACET Program data can allow clinicians to focus improvement efforts on the most prominent component of poor control (symptoms, exacerbations, and lung function).
Implementation of the guidelines-based ACET Program to standardize asthma control-level determination and appropriate treatment step supported gaining and maintaining asthma control in high-risk inner-city asthmatic children and adolescents participating in RCTs. ACET Program use in future ICAC protocols, as well as other RCTs, could facilitate high fidelity to treatment algorithms in both clinical efficacy and comparative effectiveness protocols. ACET Program use in clinical settings also could facilitate more extensive implementation of guidelines-based care among children with health disparities and traditionally more difficult-to-control asthma.
Clinical implications: A computerized decision support tool for pediatric asthma management that standardizes assessment and treatment steps can improve control among high-risk patients enrolled in multicenter RCTs; clinical adaptation is also feasible.
